PIK3CA and neoplasm: In conclusion, the combinatorial and sequential treatment of RAS/PI3K/RAF-targeted therapies after first-line immunotherapy may extend the anti-tumor response for TNBC and melanoma patients, especially those who harbor alterations in both the PI3K/AKT/mTOR and MAPK/MEK/ERK pathways.